NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
July 19, 2005 • Volume 2 / Number 29 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Director's Update
A Message from NCI Director Dr. Andrew C. von Eschenbach

Spotlight
Radiofrequency Ablation Making Inroads as Cancer Treatment

RFA: A Talented Treatment Partner

Cancer Research Highlights
Prostate Cancer PSA Testing Limitations Demonstrated

High-Risk HPVs Confirmed as Clinical Markers for Cervical Precancer and Cancer

Youth Smoking Behaviors Reduced by State-Sponsored TV Ads

New Clues in Regulation of DNA Duplication

Funding Opportunities

Featured Clinical Trial
Targeted Combination Therapy for Advanced Solid Tumors

Notes
2005 NIH Director's Awards Ceremony

Cancer PSAs Air on Soap Opera

Blumenthal to Head New CCR Nanobiology Program

CCR Grand Rounds

Bulletin Archive

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Funding Opportunities

Following are newly released NCI research funding opportunities:
Featured Meetings and Events
A calendar of scientific meetings and events sponsored by the National Institutes of Health is available at http://calendar.nih.gov
/cgi-bin/calendar

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01 and R21)
PA-05-137
Application Receipt Dates: Oct. 1, 2005; Feb. 1, June 1, and Oct. 1, 2006; Feb. 1, June 1, and Oct. 1, 2007; Feb. 1 and June 1, 2008

This funding opportunity will use the R01 and R21 award mechanisms. For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa
_id=2846
.

Inquiries: Dr. John Cole - jc121b@nih.gov; Dr. Asad Umar - au17z@mail.nih.gov; Dr. Heng Xie - XieHe@mail.nih.gov

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01)
PA-05-138
Application Receipt Dates: Oct. 1, 2005; Feb. 1, June 1, and Oct. 1, 2006; Feb. 1, June 1, and Oct. 1, 2007; Feb. 1 and June 1, 2008

This funding opportunity will use the P01 award mechanism.

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2847.

Inquiries: Dr. John Cole - jc121b@nih.gov; Dr. Asad Umar - au17z@mail.nih.gov; Dr. Heng Xie - XieHe@mail.nih.gov

Short-Term Courses in Human Embryonic Stem Cell Culture Techniques
PAR-05-133
Letter of Intent Receipt Date: August 8, 2005.
Application Receipt Date: September 8, 2005

This is a renewal of PA-02-054. This funding opportunity will use the T15 award mechanism.

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2848.

Inquiries: Dr. John Sogn - JS150x@nih.gov

Ruth L. Kirschstein NRSA Fellowships in Cancer Nanotechnology Research
RFA-CA-06-010
Application Receipt Date: November 16, 2005

This funding opportunity will use the F32 and F33 award mechanisms.

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2849.

Inquiries: Dr. Gregory J. Downing - downingg@mail.nih.gov

Research on Research Integrity
RFA-NR-06-001
Letter of Intent Receipt Date: August 16, 2005.
Application Receipt Date: September 16, 2005

This is a renewal of RFA-NS-05-003. This funding opportunity will use the R01 award mechanism.

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2850.

Inquiries: Dr. Ann O'Mara - Omaraa@mail.nih.gov.

For comprehensive information about NCI funding priorities and opportunities, go to http://www.cancer.gov/researchandfunding.

The NIH Roadmap for Medical Research Funding provides a framework of the priorities NIH must address to optimize its research portfolio. It identifies the most compelling opportunities in three main areas: new pathways to discovery, research teams of the future, and re-engineering the clinical research enterprise. For information on additional Roadmap funding opportunities, go to http://nihroadmap.nih.gov.

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov